The present study investigated the economic outcomes of implementing ELA or SOC regimens as a later-line therapy for patients who were previously treated, with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer from third-party payers in the United States. The gene discussed is ERBB2; the disease is breast carcinoma.